<p>Predictors and odds ratios for death in visceral leishmaniasis and HIV co-infected patients treated with a combination of liposomal amphotericin B (AmBisome) and miltefosine by MSF in Ethiopia from January 2011 to August 2014 (N = 173).</p
BackgroundThe long-term treatment outcome of visceral leishmaniasis (VL) patients with HIV co-infect...
BackgroundVisceral leishmaniasis (VL) in human immunodeficiency virus (HIV) co-infected patients req...
<div><p>Background</p><p>A proportion of all immunocompetent patients treated for visceral leishmani...
<p>Predictors and odds ratios for initial parasitological failure in visceral leishmaniasis and HIV ...
<p>Initial treatment outcomes of visceral leishmaniasis and HIV co-infected patients treated with a ...
North-west Ethiopia faces the highest burden world-wide of visceral leishmaniasis (VL) and HIV co-in...
<p>Demographic and clinical characteristics of visceral leishmaniasis and HIV co-infected patients t...
<div><p>Background</p><p>North-west Ethiopia faces the highest burden world-wide of visceral leishma...
North-west Ethiopia faces the highest burden world-wide of visceral leishmaniasis (VL) and HIV co-in...
Visceral Leishmaniasis (VL; also known as kala-azar) is an ultimately fatal disease endemic in the I...
Background: Visceral Leishmaniasis (VL; also known as kala-azar) is an ultimately fatal disease ende...
<div><p>Background</p><p>Visceral Leishmaniasis (VL; also known as kala-azar) is an ultimately fatal...
In Ethiopia, case fatality rates among subgroups of visceral leishmaniasis (VL) patients are high. A...
In Ethiopia, case fatality rates among subgroups of visceral leishmaniasis (VL) patients are high. A...
Visceral Leishmaniasis (VL; also known as kala-azar) is an ultimately fatal disease endemic in the I...
BackgroundThe long-term treatment outcome of visceral leishmaniasis (VL) patients with HIV co-infect...
BackgroundVisceral leishmaniasis (VL) in human immunodeficiency virus (HIV) co-infected patients req...
<div><p>Background</p><p>A proportion of all immunocompetent patients treated for visceral leishmani...
<p>Predictors and odds ratios for initial parasitological failure in visceral leishmaniasis and HIV ...
<p>Initial treatment outcomes of visceral leishmaniasis and HIV co-infected patients treated with a ...
North-west Ethiopia faces the highest burden world-wide of visceral leishmaniasis (VL) and HIV co-in...
<p>Demographic and clinical characteristics of visceral leishmaniasis and HIV co-infected patients t...
<div><p>Background</p><p>North-west Ethiopia faces the highest burden world-wide of visceral leishma...
North-west Ethiopia faces the highest burden world-wide of visceral leishmaniasis (VL) and HIV co-in...
Visceral Leishmaniasis (VL; also known as kala-azar) is an ultimately fatal disease endemic in the I...
Background: Visceral Leishmaniasis (VL; also known as kala-azar) is an ultimately fatal disease ende...
<div><p>Background</p><p>Visceral Leishmaniasis (VL; also known as kala-azar) is an ultimately fatal...
In Ethiopia, case fatality rates among subgroups of visceral leishmaniasis (VL) patients are high. A...
In Ethiopia, case fatality rates among subgroups of visceral leishmaniasis (VL) patients are high. A...
Visceral Leishmaniasis (VL; also known as kala-azar) is an ultimately fatal disease endemic in the I...
BackgroundThe long-term treatment outcome of visceral leishmaniasis (VL) patients with HIV co-infect...
BackgroundVisceral leishmaniasis (VL) in human immunodeficiency virus (HIV) co-infected patients req...
<div><p>Background</p><p>A proportion of all immunocompetent patients treated for visceral leishmani...